维基百科中的医学内容
仅供参考,并
不能视作专业意见。如需获取医疗帮助或意见,请咨询专业人士。详见
医学声明。
GS-6620是一种核苷酸类的抗病毒药物,被开发用于治疗丙型肝炎。尽管它在早期测试中显示出有效的抗病毒作用[1][2],但由于它在肠道中的吸收率低且效果不稳定(无法预测血液中的浓度),未能成功制成口服剂。[3][4]目前进行的研究主要针对其它疾病(如埃博拉出血热)[5][6]的治疗。
Quick Facts 临床资料, 商品名(英语:Drug nomenclature) ...
GS-6620![Thumb](//upload.wikimedia.org/wikipedia/commons/thumb/6/6f/GS-6620_structure.png/220px-GS-6620_structure.png) |
|
商品名 | GS-6620 |
---|
|
法律规范 |
|
---|
|
[(2R,3R,4R,5R)-5-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyl-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate
|
CAS号 | 1350735-70-4 |
---|
PubChem CID | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
CompTox Dashboard (EPA) | |
---|
|
化学式 | C29H37N6O9P |
---|
摩尔质量 | 644.6 |
---|
3D模型(JSmol) | |
---|
C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)(C)O)OC(=O)C(C)C)OC4=CC=CC=C4
|
InChI=1S/C29H37N6O9P/c1-17(2)26(36)42-24-22(43-29(15-30,28(24,6)38)23-13-12-21-25(31)32-16-33-35(21)23)14-40-45(39,44-20-10-8-7-9-11-20)34-19(5)27(37)41-18(3)4/h7-13,16-19,22,24,38H,14H2,1-6H3,(H,34,39)(H2,31,32,33)/t19-,22+,24+,28+,29-,45?/m0/s1 Key:YAAQYJCOIFNMKX-CVANIGNKSA-N
|
Close
Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, et al. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. Journal of Medicinal Chemistry. March 2014, 57 (5): 1812–25. PMID 23547794. doi:10.1021/jm400201a.
Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs. September 2014, 23 (9): 1211–23. PMID 24848437. doi:10.1517/13543784.2014.921680.
De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chemistry, an Asian Journal. November 2019, 14 (22): 3962–3968. PMID 31389664. doi:10.1002/asia.201900841.